Balyasny Asset Management
DRNA

Balyasny Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Balyasny Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-80,800
Closed -$3.02M – 2620
2021
Q2 		$3.02M Buy
+80,800
New +$2.48M 0.01% 877

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Balyasny Asset Management's DRNA Position: Q4 2021 in Review

Balyasny Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 277,949 shares — an estimated $5.6M sold.

Balyasny Asset Management first reported a position in DRNA in Q3 2018 and held it in 5 quarters. The position peaked at $5.6M in Q3 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • Balyasny Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 277,949 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $5.6M.
  • Balyasny Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2018 and held it in 5 quarters.
  • Balyasny Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $5.6M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Balyasny Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.